Results 91 to 100 of about 39,319 (333)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. [PDF]

, 2014
Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center.
Almahasnah, E, Carvajal, T, Castro, JE, Chang, J, Choi, MY, James, DF, Kipps, TJ   +6 more
core   +3 more sources

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

Cancers, 2023
Simple Summary Ibrutinib is an established standard of care in the first-line treatment of chronic lymphocytic leukemia. Since ibrutinib is given continuously, data on long-term treatment, outcomes, and safety are essential to inform clinical decision ...
J. Woyach, P. Barr, T. Kipps, J. Barrientos, I. Ahn, P. Ghia, Vincent Girardi, E. Hsu, Mandy Jermain, J. Burger   +9 more
semanticscholar   +1 more source

B cell mechanobiology in health and disease: emerging techniques and insights into therapeutic responses

FEBS Letters, EarlyView.
B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro, Marco Cellani, Cristina Scielzo   +2 more
wiley   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation.
Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose   +6 more
doaj   +1 more source

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. [PDF]

, 2019
Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered that treatment
Hasan, Md Kamrul, Kipps, Thomas J, Rassenti, Laura, Widhopf, George F, Yu, Jian   +4 more
core   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia

Case Reports in Hematology, 2021
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL).
Sara Kristina Viberg Tjønnfjord, Eirik Brekka Tjønnfjord, Zbigniew Konopski, Geir Erland Tjønnfjord   +3 more
doaj   +1 more source

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT [PDF]

, 2018
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation ...
Beelen, Dietrich, Bittenbring, Jörg, Blaise, Didier, Blok, Henric-Jan, Castagna, Luca, Chevallier, Patrice, Ciceri, Fabio, Corradini, Paolo, Eikema, Dirk-Jan, Foá, Roberto, Hallek, Michael, Hilgendorf, Inken, Koc, Yener, Kröger, Nicolaus, Moreno, Carol, Müller, Lutz Peter, Schetelig, Johannes, Selleslag, Dominik, Solano, Carlos, Theobald, Matthias, Tischer, Johanna, van Gelder, Michel, van Gorkom, Gwendolyn, van Lint, M. T.   +23 more
core   +1 more source

Disintegration of the KITENIN/ErbB4 Functional Complex by the Flavonoid Hispidulin Suppresses Colorectal Cancer Progression

Advanced Therapeutics, EarlyView.
Hispidulin disrupts the KITENIN/ErbB4 oncogenic complex and inhibits KITENIN‐mediated AP‐1 activity, cell invasion, and aerobic glycolysis. It also suppresses the production of cancer‐associated metabolites and downregulates transcriptional regulators downstream of the KITENIN complex.
Mücahit Varlı, Songjin Oh, Eunae Kim, Barış Gökalsın, Nüzhet Cenk Sesal, Kyung Keun Kim, Man Jeong Paik, Hangun Kim   +7 more
wiley   +1 more source